Intervention not reported
PPI versus prokinetic · patients with heartburn remission in gastro‐oesophageal reflux disease‐like symptoms
The intervention may leads to lower PPI versus prokinetic (low certainty).
1 finding from 1 review
Intervention not reported
PPI versus placebo · patients with heartburn remission in endoscopy negative reflux disease
The intervention probably leads to lower PPI versus placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
PPI versus H2RA · patients with heartburn remission in endoscopy negative reflux disease
The intervention may leads to lower PPI versus H2RA (low certainty).
1 finding from 1 review
Intervention not reported
PPI versus prokinetic · patients with heartburn remission in endoscopy negative reflux disease
The intervention may leads to lower PPI versus prokinetic (low certainty).
1 finding from 1 review
Clinically important upper GI bleeding · people admitted to intensive care units
H2 receptor antagonists may leads to higher clinically important upper GI bleeding compared with proton pump inhibitors (low certainty).
1 finding from 1 review
Nosocomial pneumonia · people admitted to intensive care units
H2 receptor antagonists showed no clear difference in nosocomial pneumonia compared with proton pump inhibitors (low certainty).
1 finding from 1 review
ICU mortality · people admitted to intensive care units
H2 receptor antagonists showed no clear difference in all‐cause mortality in ICU compared with proton pump inhibitors (low certainty).
1 finding from 1 review
Duration of ICU stay · people admitted to intensive care units
1 finding from 1 review
Blood transfusion · people admitted to intensive care units
H2 receptor antagonists showed no clear difference in number of participants requiring blood transfusion compared with proton pump inhibitors (moderate certainty).
1 finding from 1 review
Serious adverse events · people admitted to intensive care units
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
H2RA versus placebo · patients with heartburn remission in gastro‐oesophageal reflux disease‐like symptoms
The intervention probably leads to lower H2RA versus placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Prokinetic versus placebo · patients with heartburn remission in gastro‐oesophageal reflux disease‐like symptoms
1 finding from 1 review
Intervention not reported
H2RA versus placebo · patients with heartburn remission in endoscopy negative reflux disease
The intervention probably leads to lower H2RA versus placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality · patients with acute peptic ulcer bleeding
High showed no clear difference in mortality compared with non‐high (medium or low) dose regimen (low certainty).
1 finding from 1 review
Rebleeding · patients with acute peptic ulcer bleeding
High showed no clear difference in rebleeding compared with non‐high (medium or low) dose regimen (low certainty).
1 finding from 1 review
Surgery · patients with acute peptic ulcer bleeding
High showed no clear difference in surgery compared with non‐high (medium or low) dose regimen (low certainty).
1 finding from 1 review
Further EHT · patients with acute peptic ulcer bleeding
High showed no clear difference in further EHT compared with non‐high (medium or low) dose regimen (low certainty).
1 finding from 1 review
Length of hospital stay · patients with acute peptic ulcer bleeding
1 finding from 1 review
Blood transfusion · patients with acute peptic ulcer bleeding
1 finding from 1 review